Preclinical trials by Wei et al. combined CAR-T cells targeting PSCA with CAR-T cells targeting MUC1 in a patient-derived NSCLC xenograft mouse model, and the tumor growth was effectively inhibited [25]. Here, MUC1 is linked to neoplasm.